A series of new research projects will seek to better understand how the immune system responds to transplanted organs, including…
Articles by Marisa Wexler, MS
A new strategy for detecting very small concentrations of specific molecules could allow for better diagnosis and management of a…
The U.S. Food and Drug Administration (FDA) is reviewing applications from Vertex Pharmaceuticals to expand the approval for three…
The European Commission (EC) approved Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) to treat cystic…
ELX-02, an investigational treatment of cystic fibrosis due to nonsense mutations, has been designated an orphan drug by the…
The Scottish Government and Vertex Pharmaceuticals have reached a deal to make Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor)…
Levels of inflammatory markers in the lungs may help predict pulmonary exacerbations in children with cystic fibrosis (CF),…
Trikafta (elexacaftor/tezacaftor/ivacaftor combo) improves lung function in cystic fibrosis (CF) patients who have one F508del mutation and…
Measuring levels of a molecule called lipoarabinomannan, or LAM, in a person’s urine could be an easier way of…
The number of adults with cystic fibrosis (CF) living in the U.K. is expected to increase by at least…